Tesofensine

Also known as: NS2330

Moderate evidence
ClassTriple monoamine reuptake inhibitor
Research statusPhase 3 clinical trials
Independent tests1
Studies indexed2
Companies tested 1

Overview

A non-peptide appetite suppressant studied for obesity, frequently sold through the same channels as research peptides.

Tesofensine is classified as a triple monoamine reuptake inhibitor. Its current development status is: phase 3 clinical trials. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.

The Peptide Institute tracks Tesofensine because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Tesofensine

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
1
Samples
1
Updated
Jul 29, 2025
  1. 1 Halcyon Biosciences Excellent Institute
    Top Rated     Tesofensine

    98% average purity across 1 sample

    Purity & Testing 99 Transparency 90 Samples 1 89 View company
See the full testing database

Research & Studies

Studies library

  • Mechanistic characterization of Tesofensine receptor binding

    Frontiers in Pharmacology · Preclinical (rodent) · Jun 6, 2025

    Adds to the Tesofensine evidence base without resolving the central question of human efficacy.

  • Mechanistic characterization of Tesofensine receptor binding

    Peptides · Randomized controlled trial (Phase 2) · Aug 16, 2019

    One of the more methodologically careful entries in the Tesofensine literature.

Independent Testing

Testing database

Laboratory verification of Tesofensine products across the companies we index.

Tesofensine Halcyon Biosciences
Purity 98.0% Verified

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements